Search Results for: "Sofosbuvir"

Interventions of interest: Simeprevir (Olysio®, Janssen Products, LP) + sofosbuvir (Sovaldi®, Gilead Sciences, Inc.) Ledipasvir/sofosbuvir (Harvoni®, Gilead Sciences, Inc.) Daclatasvir (Daklinza™, Bristol-Myers Squibb Company) + sofosbuvir (Sovaldi®, Gilead Sciences, Inc.) Paritaprevir/ritonavir/ombitasvir + dasabuvir with ribavirin (Viekira Pak™, AbbVie, Inc.) Simeprevir (Olysio®, Janssen Products, LP)+ pegylated interferon and ribavirin Sofosbuvir (Sovaldi®, Gilead Sciences, Inc.) + ribavirin […]

Interventions of interest: Sofosbuvir (Sovaldi®, Gilead Sciences, Inc.)Simeprevir (Olysio®, Janssen Products, LP) Chronic hepatitis C is a common infection that is a major cause of chronic liver disease, liver failure, and hepatocellular carcinoma (HCC), and it is the leading indication for liver transplantation in the Western world. Prior to 2011, the combination of pegylated interferon […]

San Francisco, Calif., February 27, 2015 – The Institute for Clinical and Economic Review (ICER) has released the final California Technology Assessment Forum (CTAF) report “Newest Treatments for Hepatitis C, Genotype 1” and three complementary Action Guides, which reflect deliberations from the December 18, 2014 CTAF public meeting in Oakland, CA. At the meeting, the […]

San Francisco, Calif., August 18, 2014 – The California Technology Assessment Forum (CTAF), a core program of the Institute for Clinical and Economic Review (ICER), will hold a public meeting on December 18, 2014 in Oakland, CA to assess the comparative effectiveness and value of multiple new, all-oral direct-acting antiviral agent (DAA) regimens for the […]

San Francisco, Calif., May 20, 2014 – The California Technology Assessment Forum (CTAF), a core program of the Institute for Clinical and Economic Review (ICER), has released a final evidence report and three Action Guides (one each for patients, clinicians, and payers/ policymakers) on new treatments for hepatitis C. The final report and Action Guides […]

– Report will be subject of public meeting of California Technology Assessment Forum (CTAF) on March 10, 2014 – San Francisco, Calif., February 12, 2014 – The Institute for Clinical and Economic Review (ICER) has posted the draft report “The Comparative Clinical Effectiveness and Value of Simeprevir and Sofosbuvir in the Treatment of Chronic Hepatitis […]